Sugi Predict

Sugi Predict / Compounds / SCHEMBL17569999

SCHEMBL17569999

SCHEMBL17569999

Fc1cc(OCCN2CCCC2)cc(-c2nccc3[nH]c(-c4n[nH]c5ncc(-c6cn[nH]c6)cc45)nc23)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ WNT1 P04628 6/20 0.52
▸ CLK2 P49760 13/20 0.46
▸ DYRK1A Q13627 13/20 0.46
▸ CLK3 P49761 11/20 0.46
▸ TGFBR1 P36897 1/20 0.44
▸ GAK O14976 1/20 0.43
▸ DYRK3 O43781 1/20 0.43
▸ JAK2 O60674 1/20 0.43
▸ PRKD3 O94806 1/20 0.43
▸ MAP4K4 O95819 1/20 0.43
▸ NQO2 P16083 1/20 0.43
▸ CSNK2A2 P19784 1/20 0.43
▸ FECH P22830 1/20 0.43
▸ JAK1 P23458 1/20 0.43
▸ TYK2 P29597 1/20 0.43
▸ MAPK8 P45983 1/20 0.43
▸ MAPK9 P45984 1/20 0.43
▸ CSNK1A1 P48729 1/20 0.43
▸ CSNK1D P48730 1/20 0.43
▸ CSNK1E P49674 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17588803 0.92 WNT1 (0.56) WNT1CLK2DYRK1ACLK3TGFBR1
SCHEMBL17570009 0.91 WNT1 (0.60) WNT1CLK2DYRK1ACLK3TGFBR1
SCHEMBL17570023 0.91 WNT1 (0.53) WNT1CLK2DYRK1ACLK3GAK
SCHEMBL17569994 0.91 WNT1 (0.54) WNT1CLK2DYRK1ACLK3GAK
SCHEMBL17570025 0.89 WNT1 (0.54) WNT1CLK2DYRK1ACLK3TGFBR1
SCHEMBL17569997 0.89 WNT1 (0.54) WNT1CLK2DYRK1ACLK3TGFBR1
SCHEMBL17569993 0.89 WNT1 (0.56) WNT1CLK2DYRK1ACLK3TGFBR1
SCHEMBL17570002 0.89 DYRK1A (0.54) WNT1CLK2DYRK1ACLK3GSK3B
SCHEMBL17570017 0.89 WNT1 (0.54) WNT1CLK2DYRK1ACLK3TGFBR1
SCHEMBL17568619 0.89 WNT1 (0.61) WNT1CLK2DYRK1ACLK3TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10206929-B2 3-(1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2019-02-19 — — US claimed
US-20180325910-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2018-11-15 — — US claimed
US-9889140-B2 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2018-02-13 — — US claimed
US-20170224697-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2017-08-10 — — US claimed
US-9493487-B2 3-(1H-imidazo[4,5-C]pyridin-2-YL)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2016-11-15 — — US claimed
US-10206929-B2 3-(1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2019-02-19 — — US disclosed
US-9889140-B2 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2018-02-13 — — US disclosed
US-9889140-B2 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2018-02-13 — — US disclosed
US-20170224697-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2017-08-10 — — US disclosed
US-20170224697-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2017-08-10 — — US disclosed
US-9493487-B2 3-(1H-imidazo[4,5-C]pyridin-2-YL)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2016-11-15 — — US disclosed
US-9493487-B2 3-(1H-imidazo[4,5-C]pyridin-2-YL)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2016-11-15 — — US disclosed
US-20160068549-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF MED-PATHWAYS II LIMITED (VG) 2016-03-10 — — US disclosed
US-20160068549-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF MED-PATHWAYS II LIMITED (VG) 2016-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068549-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A WNT1 1/4885CLK2 2369/4885DYRK1A 949/4885
US-20170224697-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A WNT1 1/4885CLK2 2369/4885DYRK1A 949/4885
US-20180325910-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A WNT1 1/4885CLK2 2369/4885DYRK1A 949/4885
US-10206929-B2 3-(1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine and therapeutic uses thereof WNT1, WNT3, WNT3A WNT1 1/4885CLK2 2369/4885DYRK1A 949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.